NSW Awards $7 Million to Six Startups
The first round of the Emerging Technology Commercialisation Fund backs projects in medical research, agriculture and other sectors.
Updated on Nov. 18, 2026 in Startups

The New South Wales government has awarded $7 million to six startups in the first round of the Emerging Technology Commercialisation Fund. More than 250 businesses applied for funding.
Why it matters
The grants aim to help promising research move from university labs toward commercial products, with the state investing in emerging technologies. The fund is part of the NSW Innovation Blueprint 2035.
The six grants total $7 million from a three-year fund of $20 million, drawn from more than 250 applications. Celosia Therapeutics received the largest grant at $2 million, while Agscent received $1.25 million; the commercial results of the funded projects are not yet known.
The players
NSW Government
The New South Wales state government runs the Emerging Technology Commercialisation Fund as part of its Innovation Blueprint 2035 strategy.
Celosia Therapeutics
A Macquarie University spinout developing gene therapies for motor neurone disease, backed by a 2024 Series A led by Uniseed.
The details
Celosia Therapeutics, a Macquarie University spinout developing a second gene therapy for motor neurone disease, received the maximum grant of $2 million. Agscent is developing a cattle breath test to detect bovine respiratory disease in under a minute and received $1.25 million. Other recipients include Hullbot, developing a ship-mounted docking station for its hull-cleaning robot, Deteqt, a University of Sydney spinout building a magnetic sensor, and Zetifi, developing a vehicle antenna that switches between mobile towers and satellites.
Timeline
2024: Celosia raised $16.75 million in a Series A led by Uniseed.
July: Agscent raised $5 million at a $26.9 million valuation.
Last year: Hullbot closed a $6 million Series A.
2027: The next round of the commercialisation fund opens.
Market Landscape
The fund is a first concrete step under the NSW Innovation Blueprint 2035, which aims to turn university research into commercial ventures. It sits alongside private Series A rounds, such as Celosia's 2024 raise, as public and private capital work to bridge the gap between research and market.
For New South Wales residents, the grants signal public investment in local technologies that could lead to new products in healthcare and agriculture. The commercial timelines for these products are not yet set, so consumers are unlikely to see effects in the near term.
The takeaway
Public funding can help early-stage research reach the stage where private investors take it on. Watch for the next round in 2027 to see which sectors the state prioritises.
What happens next
The next round of the Emerging Technology Commercialisation Fund opens in 2027.
Further reading
Explore more on Startups to see how emerging technology ventures are being funded across the country.
Source note: This article includes information reported by Startup Daily.









